DNLI Q2 2023 Earnings — Denali Therapeutics Inc. Revenue & Financial Results | Market Cap Arena

DNLIDenali Therapeutics Inc.

$3B

Q2 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$294M+460.4% YoY

Gross Profit

$294M100.0% margin

Operating Income

$170M58.0% margin

Net Income

$183M62.3% margin

EPS (Diluted)

$1.30

QoQ Revenue Growth

+737.0%

Cash Flow

Operating Cash Flow

-$113M

Free Cash Flow

-$119M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$1.3B

Total Liabilities

$119M

Stockholders' Equity

$1.2B

Cash & Equivalents

$132M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$294M	$52M	+460.4%
Gross Profit	$294M	$52M	+460.4%
Operating Income	$170M	-$61M	+377.6%
Net Income	$183M	-$59M	+411.9%